Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

TesamorelinCheck methods and identity

What the TRIUMPH trial is designed to measure about physical function

2 numbered sourcesSource years 2026

Short chains of amino acids connected by peptide bonds can act as signals. Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with a chemical modification at its starting end. It can stimulate the pituitary to release growth hormone. A trial protocol published in July 2026 asks whether adding tesamorelin to an exercise program improves physical function in adults with HIV. [1, 2]

The protocol describes a randomized, blinded comparison of tesamorelin and placebo alongside the same exercise program. That design is intended to help distinguish changes associated with adding the drug from changes that might occur in both groups because of exercise or other parts of the study. The primary outcome is the change in how long participants take to complete a series of repeated chair stands. The test measures a movement that draws on leg strength, balance and coordination. [1]

The researchers also plan to collect other measurements, including muscle and fat images and laboratory measures of muscle tissue. These describe different aspects of the response. An image can show a difference in muscle size or composition without establishing that a person moves more easily. A timed task can show a functional change while leaving open which tissue or biological pathway contributed to it. Measuring both types of outcome can help the investigators compare the patterns. [1]

A protocol sets out a study question, comparison groups and planned measurements before results are reported. The authors explain what effect they are trying to detect and how they plan to analyze randomized participants. Those details are useful for judging the completed study when results are available. The protocol does not contain completed outcome data or show that either group improved. [1]

The approved U.S. indication for Egrifta WR is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The TRIUMPH research question concerns physical function in an exercise setting. It is a separate investigated use, with a primary measurement that directly tests performance on a task rather than assuming that a change in body composition will improve movement. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop Tesamorelin

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.